These results suggest that monitoring TAp63 and DAPK1 expression level is critical for detecting paclitaxel resistance and deciding whether to use paclitaxel in advanced or recurrent ovarian cancer patients. This evidence concerns the gene DAPK1 and ovarian cancer.